Disphar International BV merged with QPharma in June 2021 to form Sever Pharma Solutions, part of the Sever Life Sciences group (a EUR 300M organization with 900 employees). The parent entity Esperante Development focuses on pharmaceutical product innovation and development. Search results confirm Disphar's CDMO heritage with personnel who went on to CDMO roles at Novartis and other companies.
pharmaceutical development, regulatory affairs, quality assurance
1 site worldwide
Involvement in 1 clinical trial
No certifications on file yet.
No reviews available yet.
No documents available.